Despite the clinical success evidenced with the pan HDAC inhibitors, their use has been associated with some side effects, such as fatigue, diarrhea, nausea, QTc-interval prolongation and thrombocytopenia [354–357]. The gene discussed is HDAC9; the disease is Thrombocytopenia.